Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)

Eur J Pediatr. 1997 Oct;156(10):792-4. doi: 10.1007/s004310050715.


Osteoporosis is an important feature of osteogenesis imperfecta (OI). So far, no effective medical treatment is available. We treated three boys with severe OI type III and vertebral deformities for 5-7 years with continuous oral administration of the bisphosphonate, olpadronate. Treatment resulted in a decreased number of bone fractures, an increased calcification of the long bones and an amelioration of vertebral shape. No side-effects were encountered.

Conclusion: These preliminary but long-term observations suggest that the bisphosphonate olpadronate may be a useful treatment for patients with OI and vertebral fractures. Bisphosphonates may be promising drugs for children with OI.

MeSH terms

  • Body Height / drug effects
  • Bone Density / drug effects
  • Child
  • Diphosphonates / administration & dosage*
  • Diphosphonates / adverse effects
  • Follow-Up Studies
  • Humans
  • Infant
  • Long-Term Care
  • Male
  • Osteogenesis Imperfecta / drug therapy*


  • Diphosphonates
  • olpadronic acid